The Metabolomic Strategy in Tuberculosis Therapy
Ashwinee Kumar Shreshtha,
Tuberculosis causes around 1.4 million deaths every year remaining to be a major cause of
morbidity and mortality. Mycobacterium tuberculosis is adept at surviving the assault of our immune
system, which has perplexed many researchers. Not only are they difficult to treat, but also difficult
to detect accurately. The current reservoir of drugs and method to diagnose them is depleting faster
than we are able to replace them with newer one. The advances made in the field of metabolomic
have opened up a window of opportunities such as identification of new drug and druggable site,
prediction of drug toxicity and detection of new biomarkers to accurately diagnose the disease. With
its short history of less than two decades, metabolomics has shown very promising future to tackle
this concern. Equally important developments in analytical techniques and application of data
interpretation have further facilitated the scope of this field. The present review discusses the
advances in metabolomic research with an emphasis on tuberculosis diagnosis and therapeutics.
Keywords: Metabolomic, Tuberculosis, drug discovery, biomarker, NMR, MS.
Rights & PermissionsPrintExport